Identification of BIRC6 as a novel intervention target for neuroblastoma therapy

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Lamers, Fieke ^a   Schild, Linda ^a   Koster, Jan ^a   Speleman, Frank ^b   Øra, Ingrid ^c   Westerhout, Ellen M ^a   van Sluis, Peter ^a   Versteeg, Rogier ^a   Caron, Huib N ^a   Molenaar, Jan J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; BIRC6; Cancer; DIABLO; Neuroblastoma

Indexed keywords

CASPASE 9; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; NAVITOCLAX; PROTEIN BIRC5; PROTEIN BIRC6; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIRC6 GENE; CHROMOSOME 2; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC GAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; ONCOGENE; OVERALL SURVIVAL; PHENOTYPE; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; RNA HYBRIDIZATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

APOPTOSIS; CASPASE 9; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOPLASM; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; MOLECULAR TARGETED THERAPY; NEUROBLASTOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, SMALL INTERFERING;

EID: 84863675801     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-285     Document Type: Article

References (46)

1. Hao YY, Sekine K, Kawabata A, Nakamura H, Ishioka T, Ohata H, Katayama R, Hashimoto C, Zhang XD, Noda T, et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol 2004, 6:849-860. 10.1038/ncb1159, 15300255.
2. Qiu XB, Goldberg AL. The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9. J Biol Chem 2005, 280:174-182.
3. Buron N, Porceddu M, Brabant M, Desgue D, Racoeur C, Lassalle M, Pechoux C, Rustin P, Jacotot E, Borgne-Sanchez A. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 Peptides and ABT-737-induced mitochondrial membrane permeabilization. PLoS One 2010, 5(3):e9924. 10.1371/journal.pone.0009924, 2847598, 20360986.
4. Ceballos-Cancino G, Espinosa M, Maldonado V, Melendez-Zajgla J. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene 2007, 26:7569-7575. 10.1038/sj.onc.1210560, 17546047.
5. Yu J, Wang P, Ming L, Wood MA, Zhang L. SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. Oncogene 2007, 26:4189-4198. 10.1038/sj.onc.1210196, 17237824.
6. Du CY, Fang M, Li YC, Li L, Wang XD. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42. 10.1016/S0092-8674(00)00008-8, 10929711.
7. Martin SJ. An Apollon vista of death and destruction. Nat Cell Biol 2004, 6:804-806. 10.1038/ncb0904-804, 15340445.
8. Pohl C, Jentsch S. Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. Cell 2008, 132:832-845. 10.1016/j.cell.2008.01.012, 18329369.
9. Sung KW, Choi J, Hwang YK, Lee SJ, Kim HJ, Lee SH, HeeYbo K, Jung HL, Koo HH. Overexpression of apollon, an antiapoptotic protein, is associated with poor prognosis in childhood De novo acute myeloid leukemia. Clin Cancer Res 2007, 13:5109-5114. 10.1158/1078-0432.CCR-07-0693, 17785565.
10. Toujani S, Dessen P, Ithzar N, Danglot G, Richon C, Vassetzky Y, Robert T, Lazar V, Bosq J, Da Costa L, et al. High resolution genome-wide analysis of chromosomal alterations in Burkitt's Lymphoma. PLoS One 2009, 4(9):e7089. 10.1371/journal.pone.0007089, 2739276, 19759907.
11. Van Houdt WJ, Emmink BL, Pham TV, Piersma SR, Verheem A, Vries RG, Fratantoni SA, Pronk A, Clevers H, Rinkes IHMB, et al. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Mol Cell Proteomics 2011, 10(12):M111.011353. 10.1074/mcp.M111.011353, 21788403.
12. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3:203-216. 10.1038/nrc1014, 12612655.
13. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007, 369:2106-2120. 10.1016/S0140-6736(07)60983-0, 17586306.
14. Maris JM. Medical progress: recent advances in neuroblastoma. N Engl J Med 2010, 362:2202-2211. 10.1056/NEJMra0804577, 3306838, 20558371.
15. Meyer N, Penn LZ. MYC - TIMELINE Reflecting on 25 years with MYC. Nat Rev Cancer 2008, 8:976-990. 10.1038/nrc2231, 19029958.
16. Chen YY, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang LL, Soda M, Kikuchi A, Igarashi T, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974. 10.1038/nature07399, 18923524.
17. George RE, Sanda T, Hanna M, Frohling S, Luther W, Zhang JM, Ahn Y, Zhou WJ, London WB, McGrady P, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978. 10.1038/nature07397, 2587486, 18923525.
18. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970. 10.1038/nature07398, 18923523.
19. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010, 29:1566-1579. 10.1038/onc.2009.518, 20101209.
20. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935. 10.1038/nature07261, 2672043, 18724359.
21. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, et al. Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification. Clin Cancer Res 2010, 16:4353-4362. 10.1158/1078-0432.CCR-09-2660, 20719933.
22. Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J, Cuvelier CA, et al. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst 2009, 101:1562-1574. 10.1093/jnci/djp355, 19903807.
23. van Noesel MM, Versteeg R. Pediatric neuroblastomas: genetic and epigenetic 'Danse Macabre'. Gene 2004, 325:1-15.
24. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998, 351:882-883. 10.1016/S0140-6736(05)70294-4, 9525374.
25. Islam A, Kageyama H, Takada N, Kawamato T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617-623. 10.1038/sj.onc.1203358, 10698506.
26. Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, Koch T, Versteeg R, Caron HN, Molenaar JJ. Knockdown of Survivin (BIRC5) causes Apoptosis in Neuroblastoma via Mitotic Catastrophe. Endocr Relat Cancer 2011, 18:657-668. 10.1530/ERC-11-0207, 21859926.
27. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S. Multicenter Phase II Trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009, 27:4481-4486. 10.1200/JCO.2008.21.1862, 19687333.
28. Lamers F, Schild L, Koster J, Versteeg R, Caron H, Molenaar J. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer 2012, 48(5):763-771. 10.1016/j.ejca.2011.10.012, 22088485.
29. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E, Gonzalez R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2011, 29(1):161-166. 10.1007/s10637-009-9333-6, 19830389.
30. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007, 67:8014-8021. 10.1158/0008-5472.CAN-07-1343, 17804712.
31. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, et al. Phase I Study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009, 15:3872-3880. 10.1158/1078-0432.CCR-08-1946, 19470738.
32. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, et al. Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. J Clin Oncol 2008, 26:5198-5203. 10.1200/JCO.2008.17.2064, 18824702.
33. Lamers F, Schild L, den Hartog IJM, Ebus ME, Westerhout EM, Ora I, Koster J, Versteeg R, Caron HN, Molenaar JJ. Targeted BCL2 inhibition effectively inhibits Neuroblastoma tumor growth. Eur J Cancer in press.
34. Santo EE, Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, Vermeulen J, Gisselsson D, Ora I, Lindner S, et al. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene 2012, 31(12):1571-1581. 10.1038/onc.2011.344, 21860421.
35. Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJM, Versteeg R, Caron HN. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 2008, 68:2599-2609. 10.1158/0008-5472.CAN-07-5032, 18413728.
36. Fix A, Lucchesi C, Ribeiro A, Lequin D, Pierron G, Schleiermacher G, Delattre O, Janoueix-Lerosey I. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosomes Cancer 2008, 47:819-834. 10.1002/gcc.20583, 18553563.
37. Mullenbach R, Lagoda PJL, Welter C. An efficient salt-chloroform extraction of dna from blood and tissues. Trends Genet 1989, 5:391.
38. Ren JY, Shi MG, Liu RS, Yang QH, Johnson T, Skarnes WC, Du CY. The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. Proc Natl Acad Sci USA 2005, 102:565-570. 10.1073/pnas.0408744102, 543482, 15640352.
39. Basu A, Adkins B, Basu C. Down-regulation of caspase-2 by rottlerin via protein kinase c-delta-independent pathway. Cancer Res 2008, 68:2795-2802. 10.1158/0008-5472.CAN-07-6244, 18413747.
40. Nutt LK, Margolis SS, Jensen M, Herman CE, Dunphy WG, Rathmell JC, Kornbluth S. Metabolic regulation of oocyte cell death through the CaMKII-mediated phosphorylation of caspase-2. Cell 2005, 123:89-103. 10.1016/j.cell.2005.07.032, 2788768, 16213215.
41. Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG. PRIMA-1(MET) induces mitochondrial apoptosis through activation of caspase-2. Oncogene 2008, 27:6571-6580. 10.1038/onc.2008.249, 18663359.
42. Wolf M, Korja M, Karhu R, Edgren H, Kilpinen S, Ojala K, Mousses S, Kallioniemi A, Haapasalo H. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. BMC Cancer 2010, 10:181. 10.1186/1471-2407-10-181, 2873396, 20444257.
43. Lestini BJ, Goldsmith KC, Fluchel MN, Liu XY, Chen NL, Goyal B, Pawel BR, Hogarty MD. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009, 8:1587-1595. 10.4161/cbt.8.16.8964, 19556859.
44. Kushnareva Y, Newmeyer DD. Bioenergetics and cell death. Mitochondrial Res Transl Med 2010, 1201:50-57.
45. Ekert PG, Silke J, Hawkins CJ, Verhagen AM, Vaux DL. DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9. J Cell Biol 2001, 152:483-490. 10.1083/jcb.152.3.483, 2195997, 11157976.
46. Teitz T, Wei T, Liu D, Valentine V, Valentine M, Grenet J, Lahti JM, Kidd VJ. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Oncogene 2002, 21:1848-1858. 10.1038/sj.onc.1205180, 11896617.